Luye Pharma (02186.HK) announced that its innovative microsphere formulation, Jinyouping (industrialized atorvastatin microsphere for injection), independently developed by the group, has been approved for marketing by the China National Medical Products Administration as a variety included in the priority review and approval procedure for the treatment of Parkinson's disease.
綠葉製藥(02186.HK)治療帕金森創新藥金悠平獲上市批准
Luye Pharma (02186.HK) has received market approval for its innovative drug Jin Youping for the treatment of Parkinson's disease.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.